Alpha Tau Medical Ltd ((DRTS)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Alpha Tau Medical Ltd (DRTS) has announced a pivotal clinical study titled A Pivotal, Single Arm, Open Label Clinical Study to Assess the Safety and Efficacy of Intratumoral Alpha DaRT224 for the Treatment of Immunocompromised Patients With Cutaneous Squamous Cell Carcinoma. The study aims to evaluate the safety and efficacy of Alpha DaRT224, a novel treatment for cutaneous squamous cell carcinoma in immunocompromised patients. The primary objective is to measure the objective response rate, while secondary objectives include assessing progression-free survival, overall survival, and local control over 12 months.
The intervention being tested is the Diffusing Alpha-emitters Radiation Therapy (DaRT), which involves inserting radioactive DaRT seeds into tumors. These seeds release alpha-emitting atoms to target cancer cells directly, aiming to improve treatment outcomes for patients with this type of skin cancer.
The study design is interventional, single-group, and open-label, focusing on treatment as the primary purpose. There is no masking involved, and the study is conducted across multiple international centers.
The study is set to begin in December 2025, with an estimated completion date yet to be determined. The primary completion date is also pending, and the last update was submitted in July 2025. These dates are crucial for tracking the study’s progress and potential market impact.
This clinical update could influence Alpha Tau Medical’s stock performance positively, as successful results may enhance investor confidence and position the company as a leader in innovative cancer treatments. Competitors in the oncology sector will likely monitor these developments closely.
The study is ongoing, with further details available on the ClinicalTrials portal.